Valentina Rosso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5296788/publications.pdf

Version: 2024-02-01

1163117 1199594 14 242 8 12 citations h-index g-index papers 14 14 14 471 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia. Journal of Clinical Medicine, 2020, 9, 271.	2.4	10
2	Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes. Annals of Hematology, 2020, 99, 891-893.	1.8	0
3	A new BCR-ABL1 <i>Drosophila</i> model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia. Haematologica, 2019, 104, 717-728.	3.5	7
4	Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. Leukemia Research, 2018, 67, 6-11.	0.8	17
5	A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. Oncotarget, 2017, 8, 6399-6405.	1.8	7
6	The Wilms' tumor (WT 1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. Cancer Medicine, 2016, 5, 1650-1653.	2.8	8
7	Development of cellular and humoral response against <scp>WT</scp> 1 protein vaccination in mice. American Journal of Hematology, 2015, 90, E193-4.	4.1	0
8	Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. Biomarker Research, 2015, 3, 15.	6.8	8
9	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617Fmutation in Myeloproliferative Neoplasms. BMC Cancer, 2013, 13, 348.	2.6	4
10	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leukemia Research, 2013, 37, 520-530.	0.8	17
11	Deferasirox is a powerful NF-ÂB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica, 2010, 95, 1308-1316.	3.5	118
12	Genetic Abnormalities as Targets for Molecular Therapies in Myelodysplastic Syndromes. Annals of the New York Academy of Sciences, 2006, 1089, 411-423.	3.8	8
13	Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer, 2006, 106, 1188-1196.	4.1	33
14	WT1 overexpression: A clinically useful marker in acute and chronic myeloid leukemias. Hematology, 2005, 10, 76-78.	1.5	5